Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Theravance Biopharma, Inc. (TBPH) has a Wall Street consensus price target of $33.50, based on estimates from 14 covering analysts. With the stock currently trading at $18.25, this represents a potential upside of +83.6%. The company has a market capitalization of $925M.
Analyst price targets range from a low of $27.00 to a high of $40.00, representing a 39% spread in expectations. The median target of $33.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 3 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, TBPH trades at a trailing P/E of -15.9x and forward P/E of 20.2x. Analysts expect EPS to grow +59.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how TBPH stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for TBPH is $33.5, representing 83.6% upside from the current price of $18.25. With 14 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TBPH has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $33.5 implies 83.6% upside from current levels.
TBPH trades at a forward P/E of 20.2149x, representing a moderate valuation. With analysts targeting $33.5 (83.6% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $40 for TBPH, while the most conservative target is $27. The consensus of $33.5 represents the median expectation. These targets typically reflect 12-month expectations.
TBPH is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 5 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TBPH stock forecast based on 14 Wall Street analysts shows a consensus price target of $33.5, with estimates ranging from $27 (bear case) to $40 (bull case). The median consensus rating is "Buy".
TBPH trades at a forward P/E ratio of 20.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on TBPH, with a "Buy" consensus rating and $33.5 price target (83.6% upside). 6 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TBPH analyst price targets range from $27 to $40, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33.5 consensus represents the middle ground.